Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Can Urol Assoc J ; 8(9-10): E688-94, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25408808

RESUMEN

INTRODUCTION: The risk of urolithiasis post-Roux-en-Y gastric bypass (RYGB) surgery is higher when compared to the general population. Calcium and vitamin D supplementation is routinely prescribed to these patients, yet compliance with these supplements is unknown. The aim of this study was to assess the incidence of symptomatic de novo urolithiasis post-RYGB and compliance with calcium and vitamin D supplementation. METHODS: A standardized telephone questionnaire was administered to patients who underwent RYGB between 1996 and 2011. Personal and medical histories were obtained with emphasis on episodes of symptomatic urolithiasis and calcium and vitamin D supplementation. RESULTS: The response rate was 48% with 478 patients completing the telephone questionnaire. After a mean follow-up of 7.0 years (range: 1-15), the incidence of post-RYGB symptomatic urolithiasis was 7.3%, while the rate of de novo symptomatic urolithiasis was 5%. The overall median time to present with symptomatic urolithiasis was 3.1 years, with 3.3 years for de novo stone-formers, and 2.0 years for recurrent stone-formers (p = 0.38). In de novo stone-formers, 33% presented with symptomatic urolithiasis 4 to 14 years postoperatively. Compliance with calcium and vitamin D supplementation was 56% and 51%, respectively. CONCLUSIONS: Despite recall bias and lack of confirmatory imaging studies, a high postoperative incidence of symptomatic urolithiasis was found in a large sample of post-RYGB patients. A third of patients with de novo stones, presented with symptomatic urolithiasis 4 to 14 years postoperatively. Compliance with postoperative calcium and vitamin D supplementation was poor and needs improvement.

2.
J Control Release ; 161(3): 861-7, 2012 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-22634090

RESUMEN

The purpose of this work was to investigate the potential of α-cyclodextrin combined to soybean oil-based formulations to modulate the release of a model drug, indomethacin. Dry emulsion, naked and coated beads were prepared from the same initial formulation using the same manufacturing process. Dry emulsion was selected to accelerate drug release while beads coated with α-cyclodextrin were designed to sustain it. Indomethacin-loaded systems were prepared, characterised and evaluated in vitro. Pharmacokinetic studies were performed in fasted and fed rats. The presence of the α-cyclodextrin coat was confirmed by confocal microscopy, and an increase of the mass and diameter of the beads. The layer of α-cyclodextrin improved their resistance in simulated gastro-intestinal fluids. In vitro, the dissolution of indomethacin was slower with coated beads than with emulsion and naked beads. Lipid-based formulations showed an increase of relative bioavailability of IND versus Indocid®. Whatever the formulation, greater and faster release of indomethacin was noticed in sodium taurocholate-rich medium and in fed rats. Compared to naked beads, an increased Cp(max) with a shorter T(max) was observed with the emulsion while T(max) and MRT were increased and Cp(max) reduced with the coated beads. Interestingly, formulations based on alpha cyclodextrin and soybean oil can modify the release of a lipophilic drug depending on the system formed.


Asunto(s)
Portadores de Fármacos/farmacocinética , Indometacina/farmacocinética , Aceite de Soja/farmacocinética , alfa-Ciclodextrinas/farmacocinética , Administración Oral , Animales , Disponibilidad Biológica , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Emulsiones , Interacciones Hidrofóbicas e Hidrofílicas , Indometacina/administración & dosificación , Indometacina/química , Masculino , Ratas , Ratas Wistar , Aceite de Soja/administración & dosificación , Aceite de Soja/química , alfa-Ciclodextrinas/administración & dosificación , alfa-Ciclodextrinas/química
3.
Int J Pharm ; 416(2): 507-14, 2011 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-21310222

RESUMEN

The aim of this work was to investigate the stability in vitro, in simulated gastro-intestinal fluids, of beads, made of α-cyclodextrin and soybean oil, and to study the release of progesterone, a model of lipophilic drug. This was evaluated over time by the monitoring of the proportion of intact beads, their volume and the percentage of progesterone dissolved. Their incubation in the simulated gastric fluid provoked a moderate reduction of their number (20%) and a decrease of their volume (50%) after 55 min. Whatever the intestinal medium subsequently introduced, bead number and volume decreased more until bead disintegration that appeared faster in sodium taurocholate rich-medium. In such fluid, the amount of progesterone dissolved increased rapidly between 65 and 180 min, with both beads and emulsion to be equal after 85 min. With soft capsules, the increase was more gradual. In sodium taurocholate free-medium, more progesterone was dissolved from the emulsion than from beads or soft capsules. The release of progesterone from beads resulted from the erosion of their matrix and its partition equilibrium between oily micro-droplets and aqueous phase. The original structure of beads confers to this multiparticulate system interesting properties for the oral delivery of lipophilic drugs.


Asunto(s)
Sistemas de Liberación de Medicamentos , Progesterona/química , Aceite de Soja/química , alfa-Ciclodextrinas/química , Portadores de Fármacos/química , Estabilidad de Medicamentos , Emulsiones , Jugo Gástrico/metabolismo , Progesterona/administración & dosificación , Progesterona/farmacocinética , Solubilidad , Ácido Taurocólico/metabolismo , Factores de Tiempo
4.
Eur J Pharm Biopharm ; 79(1): 162-70, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21349331

RESUMEN

The aim was to synthesize and characterize fucoidan-coated poly(isobutylcyanoacrylate) nanoparticles. The nanoparticles were prepared by anionic emulsion polymerization (AEP) and by redox radical emulsion polymerization (RREP) of isobutylcyanoacrylate using fucoidan as a new coating material. The nanoparticles were characterized, and their cytotoxicity was evaluated in vitro on J774 macrophage and NIH-3T3 fibroblast cell lines. Cellular uptake of labeled nanoparticles was investigated by confocal fluorescence microscopy. Results showed that both methods were suitable to prepare stable formulations of fucoidan-coated PIBCA nanoparticles. Stable dispersions of nanoparticles were obtained by AEP with up to 100% fucoidan as coating material. By the RREP method, stable suspensions of nanoparticles were obtained with only up to 25% fucoidan in a blend of polysaccharide composed of dextran and fucoidan. The zeta potential of fucoidan-coated nanoparticles was decreased depending on the percentage of fucoidan. It reached the value of -44 mV for nanoparticles prepared by AEP with 100% of fucoidan. Nanoparticles made by AEP appeared more than four times more cytotoxic (IC(50) below 2 µg/mL) on macrophages J774 than nanoparticles made by RREP (IC(50) above 9 µg/mL). In contrast, no significant difference in cytotoxicity was highlighted by incubation of the nanoparticles with a fibroblast cell line. On fibroblasts, both types of nanoparticles showed similar cytotoxicity. Confocal fluorescence microscopy observations revealed that all types of nanoparticles were taken up by both cell lines. The distribution of the fluorescence in the cells varied greatly with the type of nanoparticles.


Asunto(s)
Antineoplásicos/toxicidad , Sistemas de Liberación de Medicamentos , Nanopartículas/toxicidad , Polisacáridos/toxicidad , Adsorción , Animales , Antineoplásicos/química , Antineoplásicos/metabolismo , Línea Celular , Cianoacrilatos/química , Cianoacrilatos/toxicidad , Composición de Medicamentos , Evaluación Preclínica de Medicamentos , Emulsiones , Enbucrilato , Excipientes/química , Fibroblastos/efectos de los fármacos , Fibroblastos/fisiología , Fluorescencia , Formazáns/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/fisiología , Ratones , Microscopía Confocal , Nanopartículas/química , Tamaño de la Partícula , Phaeophyceae , Fitoterapia , Extractos Vegetales , Polimerizacion , Polisacáridos/química , Polisacáridos/metabolismo , Sales de Tetrazolio/metabolismo
5.
Int J Periodontics Restorative Dent ; 26(1): 31-41, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16515094

RESUMEN

The restoration of anterior teeth is a difficult task, even for an experienced operator. Currently there are many different ceramic systems that can be used to achieve highly esthetic results. These include metal-ceramics with porcelain margins, Dicor, In-Ceram, Cerestore, Hi-Ceram, IPS-Empress, Cerapearl, Optec, and CAD/CAM ceramics. While metal-ceramics have been used for more than four decades, the quest for a material that transmits and refracts light like a natural tooth has inspired research into all-ceramic restorations. The purpose of this paper is to briefly discuss the properties of each of the above-mentioned materials and clinically evaluate the optical behavior of: (1) metal-ceramic crowns with castings 2 mm short of the shoulder preparation and 360-degree porcelain margins; (2) In-Ceram Spinell restorations; and (3) IPS Empress restorations, and to compare these with metal-ceramic crowns with copings to the shoulder preparation and 180-degree porcelain margins. Light transmission characteristics and color matching were subjectively evaluated by five experienced prosthodontists who did not participate in this clinical study.


Asunto(s)
Cerámica/química , Materiales Dentales/química , Porcelana Dental/química , Óxido de Aluminio/química , Silicatos de Aluminio/química , Apatitas/química , Color , Diseño Asistido por Computadora , Diseño de Prótesis Dental , Estética Dental , Femenino , Humanos , Luz , Aleaciones de Cerámica y Metal/química , Óptica y Fotónica , Propiedades de Superficie , Preparación Protodóncica del Diente
6.
J Trauma ; 54(1): 121-30; discussion 130-2, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12544907

RESUMEN

BACKGROUND: Hypertonic saline (HTS) attenuates polymorphonuclear neutrophil (PMN)-mediated tissue injury after hemorrhagic shock. We hypothesized that HTS resuscitation reduces early in vivo endothelial cell (EC)-PMN interactions and late lung PMN sequestration in a two-hit model of hemorrhagic shock followed by mimicked infection. METHODS: Thirty-two mice were hemorrhaged (40 mm Hg) for 60 minutes and then given intratracheal lipopolysaccharide (10 microg) 1 hour after resuscitation with shed blood and either HTS (4 mL/kg 7.5% NaCl) or Ringer's lactate (RL) (twice shed blood volume). Eleven controls were not manipulated. Cremaster intravital microscopy quantified 5-hour EC-PMN adherence, myeloperoxidase assay assessed lung PMN content (2 1/2 and 24 hours), and lung histology determined 24-hour PMN transmigration. RESULTS: Compared with RL, HTS animals displayed 55% less 5-hour EC-PMN adherence (p = 0.01), 61% lower 24-hour lung myeloperoxidase ( p= 0.007), and 57% lower mean 24-hour lung histologic score ( p= 0.027). CONCLUSION: Compared with RL, HTS resuscitation attenuates early EC-PMN adhesion and late lung PMN accumulation in hemorrhagic shock followed by inflammation. HTS resuscitation may attenuate PMN-mediated organ damage.


Asunto(s)
Modelos Animales de Enfermedad , Endotelio Vascular/inmunología , Fluidoterapia/métodos , Infiltración Neutrófila/inmunología , Neutrófilos/inmunología , Síndrome de Dificultad Respiratoria/etiología , Resucitación/métodos , Solución Salina Hipertónica/uso terapéutico , Sepsis/complicaciones , Sepsis/tratamiento farmacológico , Choque Hemorrágico/complicaciones , Choque Hemorrágico/tratamiento farmacológico , Animales , Evaluación Preclínica de Medicamentos , Endotelio Vascular/efectos de los fármacos , Escherichia coli , Inflamación , Soluciones Isotónicas/farmacología , Soluciones Isotónicas/uso terapéutico , Lipopolisacáridos/efectos adversos , Masculino , Ratones , Ratones Endogámicos , Neutrófilos/efectos de los fármacos , Peroxidasa/análisis , Distribución Aleatoria , Síndrome de Dificultad Respiratoria/enzimología , Síndrome de Dificultad Respiratoria/patología , Síndrome de Dificultad Respiratoria/prevención & control , Lactato de Ringer , Solución Salina Hipertónica/farmacología , Sepsis/inmunología , Choque Hemorrágico/inmunología , Método Simple Ciego , Factores de Tiempo
7.
J Urol ; 157(6): 2381-7, 1997 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9146675

RESUMEN

The effect of a Pygeum africanum extract (Tadenan) (Pa), used in the treatment of micturition disorders associated with BPH, has been examined on the proliferation of rat prostatic stromal cells stimulated by different growth factors. EGF, bFGF, and IGF-I but not KGF are mitogenic for prostatic fibroblasts in culture. Pygeum africanum inhibits both basal and stimulated growth with IC50 values of 4.5, 7.7 and 12.6 micrograms./ml. for EGF, IGF-I and bFGF, respectively, compared to 14.4 micrograms./ml. for untreated cells, the inhibition being stronger towards EGF. Pygeum africanum inhibited the proliferation induced by TPA or PDBu in a concentration-dependent manner with IC50 values of 12.4 and 8.1 micrograms./ml. respectively. The antiproliferative effects of Pa were not ascribed to cytotoxicity. These results show that Pygeum africanum is a potent inhibitor of rat prostatic fibroblast proliferation in response to direct activators of protein kinase C, the defined growth factors bFGF, EGF and IGF-I, and the complex mixture of mitogens in serum depending on the concentration used. PKC activation appears to be an important growth factor-mediated signal transduction for this agent. These data suggest that therapeutic effect of Pygeum africanum may be due at least in part to the inhibition of growth factors responsible for the prostatic overgrowth in man.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Alcoholes Grasos/farmacología , Factores de Crecimiento de Fibroblastos , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Próstata/citología , Animales , Carcinógenos/farmacología , División Celular/efectos de los fármacos , ADN/biosíntesis , Relación Dosis-Respuesta a Droga , Factor de Crecimiento Epidérmico/farmacología , Factor 10 de Crecimiento de Fibroblastos , Factor 2 de Crecimiento de Fibroblastos/farmacología , Factor 7 de Crecimiento de Fibroblastos , Sustancias de Crecimiento/farmacología , Factor I del Crecimiento Similar a la Insulina/farmacología , Masculino , Forbol 12,13-Dibutirato/farmacología , Extractos Vegetales , Ratas , Ratas Sprague-Dawley , Acetato de Tetradecanoilforbol/farmacología
8.
Calcif Tissue Int ; 56(4): 268-73, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7767836

RESUMEN

In order to test the hypothesis that salmon calcitonin has direct effects to modulate tyrosyl-protein phosphorylation in human osteosarcoma cells, SaOS-2 cells (with very high steady-state levels of skeletal alkaline phosphatase) were exposed to calcitonin, in duplicate serum-free cultures, at concentrations ranging from 10(-13) to 10(-9) mol/liter, for 0-60 minutes at 37 degrees C. Phospho-tyrosyl proteins were identified by autoradiography of Western blots after incubation with 125I-labeled antiphosphotyrosine antibodies (or with unlabeled antibodies and 125I-labeled protein A) and quantitated by laser densitometry. The results of these studies revealed (1) time-dependent effects of salmon calcitonin (sCt) (at 3 x 10(-12) mol/liter) to increase the level of tyrosylphosphorylation of at least six proteins, with apparent molecular weights of 20, 25, 27, 41, 48, and 135 kD (P < 0.05 for each); and (2) dose-dependent effects of sCt (during 15 minutes of exposure) to increase the level of tyrosyl-phosphorylation of at least 10 proteins with apparent molecular weights of 19, 20, 27, 35, 41, 102, 135, 195, 220, and 244 kD (P < 0.05 for each). A supplementary study of calcitonin effects on tyrosyl-protein phosphorylation in a subpopulation of SaOS-2 cells with very low steady-state levels of skeletal alkaline activity revealed similar responses--time and dose-dependent increases in the tyrosyl-phosphorylation of at least seven proteins with apparent molecular weights of 44, 48, 57, 62, 101, 244, and 280 kD (P < 0.05 for each).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Calcitonina/farmacología , Proteínas/efectos de los fármacos , Fosfatasa Alcalina , Diferenciación Celular , Relación Dosis-Respuesta a Droga , Humanos , Osteoblastos/citología , Osteoblastos/efectos de los fármacos , Osteosarcoma , Fosforilación/efectos de los fármacos , Proteínas/metabolismo , Factores de Tiempo , Células Tumorales Cultivadas , Tirosina/metabolismo
9.
Calcif Tissue Int ; 56(2): 154-9, 1995 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-7736325

RESUMEN

Recent studies indicate that the amount of alkaline phosphatase (ALP) activity in human osteoblast-line cells is proportional to the concentration of phosphate in the culture medium. The current studies were intended to extend those observations and to determine whether the effects of phosphate (and phosphate esters and analogs) to alter the cellular level of ALP activity, in human osteosarcoma SaOS-2 cells, reflected regulation at the level of transcription. Consistent with previous findings, we found direct, time- and dose-dependent correlations between the concentration of phosphate and the amount of ALP activity/mg cell protein (P < 0.05). Surprisingly, we also found a negative correlation between the phosphate concentration in the medium and the level of skeletal ALP mRNA (e.g., r = -0.98, P < 0.01 at 24 hours). As the highest cellular levels of skeletal ALP activity were associated with the lowest levels of ALP mRNA, these data indicated that the phosphate-dependent increase in ALP activity was not mediated by an increase in transcription and, conversely, that the effect of phosphate withdrawal to decrease ALP activity was not mediated by a decrease in transcription.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Fosfatasa Alcalina/metabolismo , Osteosarcoma/enzimología , Fosfatos/farmacología , Fosfatasa Alcalina/genética , Secuencia de Bases , ADN Complementario/genética , Relación Dosis-Respuesta a Droga , Glicerofosfatos/farmacología , Humanos , Datos de Secuencia Molecular , Osteosarcoma/genética , Fosfatos/administración & dosificación , ARN Mensajero/genética , ARN Mensajero/metabolismo , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/enzimología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA